

A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study)

Bradbury, Charlotte; Fletcher, Kate; Sun, Yongzhong; Heneghan, Carl J.; Gardiner, Chris; Roalfe, Andrea; Hardy, Polly; McCahon, Debbie; Heritage, Gail; Shackelford, Helen; Hobbs, Richard; Fitzmaurice, David

DOI:
[10.1111/bjh.16275](https://doi.org/10.1111/bjh.16275)

License:
Other (please specify with Rights Statement)

Document Version
Peer reviewed version

Citation for published version (Harvard):
Bradbury, C, Fletcher, K, Sun, Y, Heneghan, CJ, Gardiner, C, Roalfe, A, Hardy, P, McCahon, D, Heritage, G, Shackelford, H, Hobbs, R & Fitzmaurice, D 2019, 'A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study)', *British Journal of Haematology*. <https://doi.org/10.1111/bjh.16275>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is the peer reviewed version of figures from the following article: Bradbury, C., Fletcher, K., Sun, Y., Heneghan, C., Gardiner, C., Roalfe, A., Hardy, P., McCahon, D., Heritage, G., Shackelford, H., Hobbs, R. and Fitzmaurice, D. (2019) A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study), *British Journal of Haematology*, which has been published in final form at <https://doi.org/10.1111/bjh.16275>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.


Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.


Download date: 23. Apr. 2024

Figure 1A- Patient Flow



* Data for suspected DVT or PE are taken from site screening logs and are therefore only estimates of the total number with DVT or PE.

Figure 1B- Patient Flow following randomisation





* Includes 4 participants who withdrew consent to use their data


** Includes 1 participant who withdrew consent to use their data

*** Includes 2 patients receiving rivaroxaban therapy

Figure 2- Cumulative risk of the primary outcome of time to first recurrent venous thromboembolism (Panel A) and of the secondary outcomes of time to first major bleeding (Panel B), and time to first clinically relevant non-major bleeding event (Panel C) between discontinued and extended AT groups



C: Clinically relevant non-major bleeding



Number at risk					
Discontinued AT	132	119	116	110	0
Extended AT	135	118	108	101	0